Advanced Solid Tumor Clinical Trials in Seattle, Washington

12 studies are recruiting for advanced solid tumor in Seattle, Washington right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

   This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma [cutaneous/acral], squamous cell carcinomas of the head and neck (SCCHN), HER2-negative gastric can…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Fred Hutchinson Cancer Center, Seattle, Washington

   Locations

   90 in total

   Run by

   Daiichi Sankyo

   See if you can join NCT06172478 on ClinicalTrials.gov

2. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

   The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   University of Washington, Fred Hutchinson Cancer Center, Seattle, Washington

   Locations

   77 in total

   Run by

   PMV Pharmaceuticals, Inc

   See if you can join NCT04585750 on ClinicalTrials.gov

3. A Study of KK2269 in Adult Participants With Solid Tumors

   This is a first-in-human study of KK2269. Part 1 and Part 2 will be conducted as a multicenter, open-label, non-randomized, dose-escalation study. Participants with advanced or metastatic solid tumors for which no standard therapy is available will be enrolled in Part 1. In Part 1, the primary obje…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Washington, Seattle, Washington

   Locations

   32 in total

   Run by

   Kyowa Kirin Co., Ltd.

   See if you can join NCT06266299 on ClinicalTrials.gov

4. Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

   This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Local Institution - 134, Seattle, Washington

   Locations

   25 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT05245500 on ClinicalTrials.gov

5. A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors

   The goal of this clinical trial is to learn if BGB-B455 can treat advanced or metastatic solid tumors expressing claudin 6 (CLDN6), a protein that is found on some tumors. The main questions it aims to answer are: * What is the recommended dosing for BGB-B455? * What medical problems do participant…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Fred Hutchinson Cancer Research Center, Seattle, Washington

   Locations

   11 in total

   Run by

   BeOne Medicines

   See if you can join NCT06803680 on ClinicalTrials.gov

6. A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

   The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy and in combination with enzalutamide, in patients with advanced solid t…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Swedish Cancer Institute, Seattle, Washington

   Locations

   80 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT04104776 on ClinicalTrials.gov

7. An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors

   The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75202 (KAT6A/B inhibitor) alone and in combination with other therapies in participants with breast cancer and other advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Fred Hutchinson Cancer Research Center, Seattle, Washington

   Locations

   31 in total

   Run by

   BeOne Medicines

   See if you can join NCT07222267 on ClinicalTrials.gov

8. SLV-154 Treatment of Advanced Cancers

   This is a Phase 1 study comprising a Phase 1a dose-escalation portion and a Phase 1b expansion portion evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-154 across a range of dose levels when administered to subjects with advanced solid tumors.

   Stage

   Phase 1

   Ages

   12 and older

   Site

   University of Washington / Fred Hutchinson Cancer Center, Seattle, Washington

   Locations

   10 in total

   Run by

   Solve Therapeutics

   See if you can join NCT06771219 on ClinicalTrials.gov

9. A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors

   The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C137 alone and in combination with anticancer agents in participants with advanced solid tumors. The study will be conducted in two phases: Phase 1a (…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Fred Hutchinson Cancer Research Center, Seattle, Washington

   Locations

   52 in total

   Run by

   BeOne Medicines

   See if you can join NCT06625593 on ClinicalTrials.gov

10. A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

    Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Fred Hutchinson Cancer Center, Seattle, Washington

    Locations

    21 in total

    Run by

    Clasp Therapeutics, Inc.

    See if you can join NCT06778863 on ClinicalTrials.gov

11. A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

    This is a Phase 2, multi center, open-label study to evaluate the safety and efficacy of Type II RAF (tovorafenib) in pediatric participants with low-grade glioma or advanced solid tumors. Qualifying genomic alterations will be identified through molecular assays as routinely performed at Clinical …

    Stage

    Phase 2

    Ages

    0 to 25

    Site

    Seattle Children's Hospital, Seattle, Washington

    Locations

    35 in total

    Run by

    Day One Biopharmaceuticals, Inc.

    See if you can join NCT04775485 on ClinicalTrials.gov

12. AIMS Cancer Outcomes Study

    The overall aim is to describe disease-free survival (DFS) in early stage cancer patients and three-year overall survival (OS) outcomes in advanced stage cancer patients receiving Advanced Integrative Oncology (AIO) treatment in a prospective consecutive case series outcomes study. We will collect …

    Stage

    Not phased

    Ages

    Any age

    Site

    AIMS Institute, Seattle, Washington

    Run by

    Advanced Integrative Medical Science Institute

    See if you can join NCT04495790 on ClinicalTrials.gov